CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略
Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.
胰腺癌仍然是全球最致命的恶性肿瘤之一,其中胰腺导管腺癌(PDAC)占大多数病例,且预后持续不佳。
ALL SOURCES
Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.
胰腺癌仍然是全球最致命的恶性肿瘤之一,其中胰腺导管腺癌(PDAC)占大多数病例,且预后持续不佳。
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies.
胃肠道恶性肿瘤(GIM)给全球健康带来了沉重负担,约占全球癌症相关死亡率的33%。
Challenges and recent advances in CAR-T cell therapy for solid tumors.
CAR-T 细胞疗法在血液系统恶性肿瘤中取得了革命性成功。
From antigen to atlas: A multi-omics, single-cell pipeline for discovering safe and effective CAR targets in ovarian cancer.
嵌合抗原受体(CAR)T细胞疗法在血液系统恶性肿瘤中取得了显著成功,但在卵巢癌(OC)等实体瘤中仍面临重大障碍,主要归因于抗原异质性和靶向非肿瘤毒性。
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
我们以三种CT041剂量之一治疗了37例患者:2.5 10 8、3.75 10 8或5.0 10 8个细胞。
Chimeric antigen receptor T-cell therapy for solid tumors: A review of the intricate mechanisms and potential strategies.
CAR-T 细胞疗法已经彻底改变了癌症免疫治疗,在血液系统恶性肿瘤中取得了显著成功。
Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor.
SNR CAR-T细胞方法解决了肿瘤抗原异质性和抑制性肿瘤微环境的问题,为实体瘤提供了一种有前景的治疗策略,并为其未来的临床应用铺平了道路。
IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor
靶向IDO1是克服胃肠道癌症免疫抑制屏障、提高CLDN18.2-CAR-T疗法疗效的一种有前景的策略。这些发现凸显了将IDO1抑制整合到CAR-T治疗方案中以解决难治性癌症耐药问题的潜力。
In Situ Generation of Claudin18.2-Specific CAR-T Cells via Lipid Nanoparticle-Mediated mRNA Delivery.
嵌合抗原受体(CAR)T细胞疗法在血液系统恶性肿瘤中取得了显著的临床成功;然而,其更广泛的应用受到高制造成本和对实体瘤疗效不足的限制。
Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing.
CAR-T 细胞(CAR T)疗法已成功用于治疗血液系统恶性肿瘤。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。